ANAB (AnaptysBio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ANAB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Daniel Faga | President, CEO | A | — | — |
| 2026-08-07 | Paul F. Lizzul | Chief Medical Officer | A | — | — |
| 2026-08-07 | Daniel Faga | President, CEO | A | — | — |
| 2026-08-07 | Paul F. Lizzul | Chief Medical Officer | A | — | — |
| 2026-06-17 | John A Orwin | Director | M | — | — |
| 2026-06-17 | HOLLINGS RENTON | Director | M | — | — |
| 2026-06-17 | John P. Schmid | Director | M | — | — |
| 2026-05-13 | Owen Hughes | Director | A | — | — |
| 2026-05-13 | Christopher M. Murphy | Chief Financial Officer | A | — | — |
| 2026-04-29 | SUSANNAH GRAY | Director | A | — | — |
| 2026-04-23 | Daniel Faga | President, CEO | D | — | — |
| 2026-04-22 | John A Orwin | Director | MIXED | — | — |
| 2026-04-22 | John P. Schmid | Director | MIXED | — | — |
| 2026-04-22 | Daniel Faga | President, CEO | MIXED | — | — |
| 2026-04-22 | HOLLINGS RENTON | Director | MIXED | — | — |
| 2026-04-01 | John P. Schmid | Director | Sell | — | — |
| 2026-03-27 | Daniel Faga | President, CEO | MIXED | — | — |
| 2026-02-13 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2026-01-16 | Magda Marquet | Director | MIXED | — | — |
| 2026-01-09 | Daniel Faga | President, CEO | MIXED | — | — |
| 2026-01-09 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2026-01-09 | DENNIS MULROY | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-01-09 | Paul F. Lizzul | Chief Medical Officer | MIXED | — | — |
| 2026-01-08 | Rita Jain | Director | A | — | — |
| 2026-01-08 | John A Orwin | Director | A | — | — |
| 2026-01-08 | Paul F. Lizzul | Chief Medical Officer | MIXED | — | — |
| 2026-01-08 | DENNIS M FENTON | Director | A | — | — |
| 2026-01-08 | HOLLINGS RENTON | Director | A | — | — |
| 2026-01-08 | J. Anthony Ware | Director | A | — | — |
| 2026-01-08 | Magda Marquet | Director | A | — | — |
| 2026-01-08 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2026-01-08 | John P. Schmid | Director | A | — | — |
| 2026-01-08 | Daniel Faga | President, CEO | MIXED | — | — |
| 2026-01-08 | DENNIS MULROY | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-01-06 | Daniel Faga | President, CEO | MIXED | — | — |
| 2026-01-06 | DENNIS MULROY | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-01-06 | Paul F. Lizzul | Chief Medical Officer | MIXED | — | — |
| 2026-01-06 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2025-12-23 | J. Anthony Ware | Director | Sell | — | — |
| 2025-12-23 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2025-12-23 | John P. Schmid | Director | J | — | — |
| 2025-12-23 | Paul F. Lizzul | Chief Medical Officer | MIXED | — | — |
| 2025-12-23 | DENNIS MULROY | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-12-18 | DENNIS MULROY | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-12-18 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2025-10-01 | ERIC J LOUMEAU | CHIEF LEGAL OFFICER | MIXED | — | — |
| 2025-09-17 | John A Orwin | Director | M | — | — |
| 2025-08-12 | HOLLINGS RENTON | Director | MIXED | — | — |
| 2025-07-03 | HOLLINGS RENTON | Director | MIXED | — | — |
| 2025-06-20 | HOLLINGS RENTON | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,880,094 | — |
| — | Director | 7,521,024 | — |
| — | 10%+ Owner | 3,319,224 | — |
| — | 10%+ Owner | 2,345,612 | — |
| — | 10%+ Owner | 1,936,604 | — |
| — | 10%+ Owner | 1,636,945 | — |
| — | 10%+ Owner | 1,337,795 | — |
| — | 10%+ Owner | 973,612 | — |
| — | 10%+ Owner | 929,491 | — |
| — | President, CEO | 505,862 | — |
| — | Director | 280,341 | — |
| — | Director | 276,131 | — |
| — | President, CEO | 93,330 | — |
| — | Chief Medical Officer | 68,579 | — |
| — | Director | 64,296 | — |
| — | Chief Medical Officer | 42,088 | — |
| — | Director | 37,652 | — |
| — | CHIEF FINANCIAL OFFICER | 24,367 | — |
| — | CHIEF LEGAL OFFICER | 22,835 | — |
| — | Director | 16,695 | — |
| — | Director | 11,864 | — |
| — | Director | 11,640 | — |
| — | Director | 10,995 | — |
| — | Director | 9,630 | — |
| — | Director | 4,965 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANAB quote page; the site-wide leaderboard is on the insider transactions hub.